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Abstract 
 
Background:  High flow nasal cannula therapy is becoming a more common therapy in the adult 
population.  Multiple studies have been conducted on the potential benefits of this therapy such as 
increased patient tolerance of the therapy, improved secretion clearance and the ability for providers to 
deliver a greater range of FiO2 settings at a wider range of flow rates.  With the increasing utility of this 
therapy, the research for best practices, setting (FiO2 and LPM) and duration of therapy to guide 
clinicians is lacking.   
Aim: 1) Does high flow nasal cannula therapy reduce the need for intubation or re-intubation in patients 
with hypoxic respiratory failure, as compared to continuous positive airway pressure or bi-level positive 
airway pressure therapy?  2) How do variations in setting of high flow nasal cannula therapy affect the 
need for intubation or re-intubation, mortality and hospital length of stay?   
Methods:  Subjects for this study were adults, ages 18-99 years old with a diagnosis of respiratory failure.  
Group 1 (n=213) was created to determine whether initial high flow treatment for respiratory failure may 
decrease intubation rates, as compared to continuous positive airway pressure or bi-level positive airway 
pressure therapy.  Group 2 (n=88) examined whether high flow nasal cannula therapy was associated with 
lower re-intubation rates when high flow was administered to post ventilator respiratory failure patients.  
An in-group analysis of high flow nasal cannula therapy was done in both groups to examine how 
variation in setting affected patient outcomes. Statistical analysis was performed with SPSS version 24.   
Results:  In Group 1, the analysis of high flow nasal cannula therapy vs. continuous positive airway 
pressure or bi-level positive airway pressure therapy found no significant difference in intubation rates, 
p=0.119.  No significant difference was found between type of NIV therapy used for post extubation 
patients and the rate of re-intubation for Group 2, p=0.789.  In-group analysis of high flow cannula setting 
(FiO2 and LPM) found that there was no significant difference associated with high flow administration 
and reduced mortality in Group 1 (FiO2 p=0.0988, LPM p=0.502 or Group 2 (FiO2 p=0.194, LPM 
p=0.449).  There was no significant difference in the need for intubation or re-intubation in both Group 1 
(FiO2 p=0.992, LPM p=0.716) and Group 2 (FiO2 p=0.746, LPM p=0.592).   
Conclusion: This study suggests that high flow nasal cannula therapy performed similarly as continuous 
positive airway pressure or bi-level positive airway pressure therapy in preventing intubation and re-
intubation rates.  The group analysis of high flow nasal cannula therapy settings suggests that variation in 
the setting did not impact intubation or re-intubation rates. 
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Background 
High flow nasal cannula (HFNC) therapy is a noninvasive ventilation (NIV) modality that has 
recently gained increased attention in the adult critical care world.  This form of noninvasive ventilation 
allows for the delivery of warm, humidified oxygen therapy with a FiO2, the percentage of oxygen 
inspired, of 0.21-1 and flow rates up to 60 liters per minute (LPM) (Nishimura, 2016).  HFNC therapy 
allows for a more predictable delivery of FiO2 than other noninvasive ventilation strategies (Nishimura, 
2016).   In addition, HFNC therapy has the ability to improve oxygenation (Stephan et al., 2015; Cirio et 
al., 2016) and decreases the work of breathing (Stephan et al., 2015; Roca, Riera, Torres, & Masclans, 
2010).  In a study by Frat et al. (2015), patients with a pO2/FiO2 ratio of  < 200 HFNC showed a reduced 
need for intubation when compared to standard oxygen therapy (i.e., low flow oxygen therapy) and other 
noninvasive ventilation modalities, p=0.01. This open label, multicenter, randomized control studyf 
examined the effects that HFNC therapy had on clinical outcomes and intubation rates in acute respiratory 
failure patients admitted to the intensive care unit (ICU).  The population consisted of adult patients, 18-
99, admitted to the ICU with respiratory failure secondary to community acquired pneumonia, hospital 
acquired pneumonia, extra pulmonary sepsis, aspiration/drowning, pneumonia related to 
immunosuppression and other causes (Frat et al., 2015).  This study also found that HFNC therapy leads 
to a significant reduction in ICU mortality, standard oxygen therapy vs. HFNC therapy p=0.046 and 
HFNC therapy vs. noninvasive ventilation p=0.006.  Strengths of this study were that it followed a well-
delineated research protocol, and pre determined definition of the need for intubation, and multicenter 
design.  A limitation of this study was that blinding of therapy delivered was in the selection of setting for 
HFNC therapy, as there was no documented justification for the setting used in the study.  In the study by 
Frat et al. (2015), the potential for bias was addressed by having the data masked until collection was 
completed.   
HFNC therapy was also found to have clinical benefits when applied post extubation.  When 
compared to BiPAP, HFNC was found to be non-inferior in reducing the rate of re-intubation (Hernadez 
et al., 2016; Stephan et al., 2015).  Both of these studies were well-designed, multicenter, prospective, 
randomized control trials.  Hernadez et al. (2016) examined how HFNC therapy could affect re-intubation 
rates in patients that experienced post extubation acute respiratory failure.  This study evaluated how 
HFNC performed vs. CPAP and BiPAP in reducing the re-intubation rates in patients deemed high risk 
for the need to be re-intubated.  In the study by Stephan et al. (2015), researchers examined if HFNC was 
inferior to BiPAP in preventing or reducing acute respiratory failure in postoperative cardiothoracic 
patients. Both studies followed a well-delineated study protocol and predetermined definition of outcomes 
to conduct their collection and analysis.  A limitation for both of these studies is that there is no 
documented justification for the settings that were used in the study.  In Hernandez et al. (2016), the 
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selection criteria for patient inclusion was for patients that are at higher risk for intubation, which could 
have skewed results. In addition, no current literature provides any evidences for a tool to identify these 
patients.  An additional limitation of Stephan et al. (2015) is that the therapies were not blinded.  This 
could potentially have resulted in bias in the data collection process.  
The current state of literature has been focused on the potential benefits of HFNC study.  In the 
field of HFNC therapy, research or Medical Society Consensus Statements examining the best practices 
for FiO2 and LPM setting to guide clinicians are currently lacking.  This is due to the lack of current 
literature examining the affects from variation in therapy.  It is to our knowledge that no previous studies 
have been conducted to evaluate the equipoise of practice for HFNC therapy settings. 
Aim 
This study examined a single quaternary academic medical center’s current practices of high flow 
nasal oxygen administration to identify trends in practice for variability.  In addition, this study looked at 
how current practices in HFNC therapy relate to the subsequent need for intubation or re-intubation, 
patient mortality, length of stay and time on NIV in acute respiratory failure patients.  This study will also 
examine how HFNC therapy, compared to CPAP/BiPAP, affects the need for intubation or re-intubation, 
mortality, length of stay and time mechanical ventilation.  This study will examine a single center’s 
administration of oxygen therapies prior to intubation and post-intubation in patients with acute 
respiratory failure.  In addition, this study will examine the effects that variations in HFNC therapy 
settings have on patient outcomes.  This study will help establish whether equipoise exists in the current 
single center’s practice.  Information from this study may help define future study groups in order to 
define which HFNC parameters may be best, or define which disease states might benefit most from 
administration of HFNC therapy. 
Methods 
Design 
This study was a non-experimental, descriptive, retrospective medical record review. 
Subjects 
Subjects included in this study consisted of adults 18-99 years old that developed or presented 
with acute respiratory failure and were admitted to UK Chandler Hospital and received NIV therapy 
during their stay.   Exclusion criteria included patients with tracheostomy or do-not-intubate status.  For 
inclusion in this study, each instance of NIV therapy recorded was designed, in order to be considered 
evaluable, to simultaneously coincide with a hypoxic event documented within the electronic medical 
record.  Hypoxia for this study was defined as a SpO2 < 92%, RR>20 per minute, heart rate >100 beats 
per minute and a PaO2 of less than 80.  This criterion was adapted from definitions of hypoxia from 
previous studies, Frat el al. (2015), Hernadez et al. (2016), Roca, et al. (2010) and Stephan et al. (2015).  
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Each event of NIV needed documentation of at least one of these variables up to four hours prior to the 
initiation of therapy.  If a patient had an additional encounter of NIV therapy documented within 12 hours 
of the previous NIV therapy documentation, the additional encounter was considered to be treating the 
same hypoxic event.  This study is designed so that for NIV therapy to be considered successful in 
preventing intubation, the subjects could not have been intubated and placed on mechanical ventilation 
within 12 hours of the last NIV documentation.  To determine if NIV therapy is successful in reducing the 
need for re-intubation, subjects re-intubated within 48 hours of extubation were considered as failing NIV 
therapy.   
A sample size of 400 patients was selected to ensure that the study was adequately powered to 
detect a moderate correlation and from parameters in previous randomized controlled trials (Hernadez et 
al., 2016; Stephan et al., 2015).  An electronic medical record review of the Sunrise Clinical Manager 
(SCM) database was conducted to identify BiPAP, CPAP and HFNC use in the emergency department, 
ICUs and floors of UK Medical Center. The time frame for this medical record review was July 1, 2014-
July 1, 2016.  The initial search of SCM data based produced 46,218 unique patient encounters, Figure 1. 
From this patient pool, those with a primary or secondary diagnosis of acute respiratory failure and solely 
receiving HFNC or CPAP or BiPAP were to be included for this study.  This gave the final pool of 1,885 
patients, 329 HFNC, 1,227 CPAP or BiPAP and 329 that received both therapies.  From these patients, a 
computerized random number generator was used to select 200 that only received HFNC therapy and 200 
patients that only received CPAP or BiPAP.  These patients made up the final sample of patients for this 
study.  The sample for this study was further divided in to two groups.  Group 1 comprised of patients 
that received either HFNC therapy or CPAP or BiPAP and the initial form of NIV therapy as initial 
treatment prior to the need for intubation.  Group 2 comprised of patients that received HFNC therapy or 
CPAP or BiPAP after liberation from mechanical ventilation.  Of the 400 patients, 308 meet the inclusion 
criteria for Group 1.  Of the 308 patients, 95 had to be excluded from the study due to improper 
documentation of NIV, NIV setting and discharge disposition.  This left 213 patients to be included in the 
sample for Group 1.  In Group 2, 92 patients were originally selected, but four had to be excluded due to 
incomplete charting and missing data, leaving the final sample at 88.  
Data Collection 
General patient characteristics (age, gender) and primary diagnosis were collected.  Data 
collection for HFNC, BiPAP and CPAP began at the documented time the therapy was started.  Hourly 
documented settings of HFNC, BiPAP and CPAP were collected.  If no documentation for an hour was 
available, the settings from the previous hour were used. For BiPAP, CPAP and HFNC, the amount of 
time that a subject was on a therapy was collected.  Onset of therapy was defined as the first 
documentation of settings for HFNC, BiPAP and CPAP.  The cessation of therapy was defined as the 
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documented time that HFNC, BiPAP and CPAP were discontinued or the time that another oxygen 
supportive therapy was documented.  The time of intubation was the time that post intubation chest x-rays 
were obtained to confirm endotracheal tube placement or the documentation of mechanical ventilation 
settings. 
Arterial blood gases (ABGs) documented within four hours to the initiation/change in oxygen 
therapy of therapy will be collected.  The nearest documented vital signs (heart rate, blood pressure, 
respiratory rate and SpO2) and oxygen settings (L/min) to 0700, 1100,1300,1700, 2100, 2400 (0000) and 
0300 hours were collected. 
Time on mechanical ventilation was collected.  The first documented ventilator settings of the 
day were recorded until the time of extubation.  The time of extuabtion was determined to be the 
documentation of extubation or initiation of a different oxygen supportive therapy.  Ventilator days were 
defined as any portion within a calendar day on mechanical ventilation. Hospital length of stay was 
calculated as the documented time of admission to the documented time of disposition (discharge or 
death).  Diagnosis related groups were collected on for each subject on the time of discharge.  Disposition 
location was collected.  Data collection was done through the Center for Health Service Research.  See 
Table 1 for data points recorded. 
Plan for Analysis 
Descriptive statistics were used to summarize the study sample using means and standard 
deviations, medians and ranges or frequencies and percentages.  The Chi-square test of association was 
used to compare mortality by patient category.  The Mann-Whitney U test was used to compare groups on 
non-normal clinical variables (hospital length of stay, time on mechanical ventilation and time on 
noninvasive ventilation).  An in-group analysis of HFNC therapy was done with the Mann-Whitney U 
and Kruskal-Wallis test, where appropriate, to assess how changes in FiO2 and LPM could affect the need 
for intubation, hospital length of stay, mortality, time on noninvasive therapy and time on mechanical 
ventilation. All data analysis was conducted using SPSS, version 24, with an alpha level of .05. 
Results 
Group 1: HFNC vs. CPAP or BiPAP and Intubation 
Group 1 was created to examine the effects of HFNC therapy vs. CPAP or BiPAP on preventing 
the need for intubation when delivered as initial therapy in patients with acute respiratory failure.  In this 
group, there was even distribution between patient groups, those receiving HFNC (n=88) therapy and 
those receiving CPAP or BiPAP (n=125).   Between HFNC therapy and CPAP or BiPAP, there was no 
significant difference between age (p=0.188) and sex (p= 0.216).  In each group, there was a similar 
distribution of men and women.  This is shown in Table 2.  As determined by DRG weighting, there was 
a significant difference in the patient acuity between HFNC therapy and CPAP or BiPAP, p= 0.046.  
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Table 2 shows that patients that received HFNC therapy had a higher median DRG weight than those in 
the CPAP or BiPAP group, 3.16 vs. 1.88.  The difference in DRG-determined acuity may also explain the 
significant difference in the hospital length of stay between HFNC therapy and CPAP or BiPAP, p= 
0.048.  Patients that received HFNC therapy had a median hospital length of stay of 14.82 days, and 
patients that received CPAP or BiPAP had a 10.65 days median hospital length of stay, a difference of 
4.17 days. 
Comparing CPAP or BiPAP vs. HFNC therapy for the duration of NIV treatment, a Mann-
Whitney U test indicated a significant difference between therapies and the amount of time subjects were 
on therapy, HFNC 6.50 hours, CPAP or BiPAP 4.00 hours, p=<0.001.  A Mann-Whitney U test indicated 
a significant difference in hospital length of stay, p=0.048.  A Chi-square test, with Yates Continuity 
Correction, was conducted to assess the association of HFNC therapy and mortality.  The percentage of 
subjects that expired was similar between groups, 22.4% (28) in the CPAP or BiPAP group and 27.3% 
(24) for subjects receiving HFNC therapy, p= 0.415, Table 2.  HFNC therapy was compared to CPAP or 
BiPAP to determine if one therapy was associated with a reduction in respiratory failure and a patient’s 
need for intubation, Table 3.  A Chi-square test, with Yates Continuity Correction, indicated no difference 
in intubation rates between HFNC therapy or CPAP or BiPAP, p=0.119.  There was no difference in the 
number of days a subject was on mechanical ventilation post NIV therapy, p=0.801. 
A secondary analysis of patients in Group 1 who received HFNC therapy was done. This 
secondary analysis was done to determine if different initial settings for FiO2 and LPM had any 
significant association with the need for intubation, and to determine if the settings impacted clinical 
outcomes, Table 4 and Table 5.  Between initial settings for LPM, no significant difference was found in 
patient acuity, p=0.692 (Table 5).  However, for the subjects in Group 1, there was significant difference 
in initial FiO2 settings and the acuity of the patient, p=0.003 (Table 4).  There was no significant 
difference between the quartiles of initial LPM (p=0.716) and FiO2 (p=0.992) and the need for intubation, 
Table 4 and Table 5.  The comparison of initial FiO2 and LPM setting and mortality was also assessed to 
decipher which setting was associated with reduced mortality.  Findings for this comparison showed no 
significant difference in mortality in initial FiO2 (p=0.099) and LPM settings (p=0.502).  When looking 
at variation in initial FiO2 setting, no significant difference was found between hospital length of stay, 
p=0.062, and time patients were on the ventilator post intubation, p=0.082.  There was no significant 
difference between initial LPM setting and hospital length of stay, p=0.476.  Variation in setting of initial 
LPM delivered to the patient was found to have a significant impact on the amount of time a patient was 
mechanically ventilated after receiving HFNC therapy, p=0.046.  No significant difference, p= 0.476, was 
found in patient length of stay among different flow rates.  No significant difference was found between 
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initial FiO2 settings and duration of NIV, p=0.103.  However, there was a significant difference between 
flow rate settings and the duration of NIV therapy, p=0.033. 
Group 2 HFNC vs. CPAP or BiPAP and Re-intubation 
Of the 88 patients in Group 2, 62 (70.45%) received HFNC therapy and 26 (29.55%) received 
CPAP or BiPAP.  Between HFNC therapy and CPAP or BiPAP, there was a significant difference in the 
age of the patients, p= 0.048 (Table 6).  As shown in Table 6, there was no statistical difference in the 
gender distribution between HFNC and CPAP or BiPAP, p= 0.376.  For patient acuity, there was no 
statistical difference between HFNC therapy (5.17) and CPAP or BiPAP (5.37), p= 0.905.  
When assessing HFNC therapy’s effect on hospital length of stay, there was no significant 
difference as compared to CPAP or BiPAP (16.08 vs. 18.16 days), p=0.387.  Between HFNC therapy and 
CPAP or BiPAP, there was no significant difference in mortality, HFNC vs. CPAP or BiPAP, p=0.975.  
In comparing the need for re-intubation, no significant difference, p=0.969, was found between NIV 
therapies.  As with the finding in Group 1, subjects received HFNC therapy a significantly longer amount 
of time than subjects on CPAP or BiPAP, p=<0.001.  This study found that there was a significant 
difference in the delay of initiation of NIV therapy post extubation and the need for a patient to be re-
intubated, p=0.075. 
A secondary in-group analysis of HFNC therapy was performed to establish if there was any 
difference between FiO2 settings and LPM and re-intubation.  There was no significant difference across 
quartiles for both FiO2 (p=0.746) and LPM (p=0.592) and re-intubation.  For mortality and differences in 
FiO2 therapy (p=0.194) and LPM (p=0.449) setting, no significant association was established between 
HFNC and mortality.  Variation in initial HFNC setting of FiO2 (p=0.145 and LPM (p=0.582) had no 
significant association with hospital length of stay. 
Discussion 
Findings 
The analysis comparing NIV therapies (HFNC vs. CPAP or BiPAP) showed that there was no 
significant difference in the ability of either therapy to reduce the rate of intubation.  This finding is 
consistent with the Frat et al. (2015) conclusion that HFNC therapy has no significant effect on the 
intubation of subjects with hypoxic respiratory failure.  These findings suggest that HFNC therapy is non-
inferior to CPAP or BiPAP in reducing the need for intubation.  Subjects in this study on NIV had a lower 
rate of intubations than seen in Frat et al (2015).  This could be due to the inclusion criteria for the 
subjects.  In this study, subjects who developed a secondary diagnosis of respiratory failure were 
included.  Subjects who developed respiratory failure in the hospital could have received interventions to 
treat their respiratory failure sooner than the subjects in Frat el al. (2015) that presented with the primary 
diagnosis of respiratory failure.  The difference in the ability to detect a significant difference between 
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groups could be due to this study being underpowered.  It could also be attributed to the difference in 
mortality in-groups.  Another factor that could affect the difference in mortality rates between this study 
and Frat et al. (2015) is that patients in this study could have had a higher acuity.  It is impossible to 
determine if there was a difference in acuity because different measures of acuity were used in each study.  
It is interesting to note that the amount of time a patient was on NIV therapy had a significant association 
with the need to be intubated. When looking at the amount of time a patient was on NIV, patients who 
received HFNC were on therapy significantly longer than those that received CPAP or BiPAP.   
When looking at the use of HFNC therapy in post extubation acute respiratory failure, findings in 
this study suggest that HFNC therapy had no significant difference in effecting the rate of re-intubation.  
This finding suggests that HFNC therapy is non-inferior to CPAP or BiPAP in reducing the need for re-
intubation in patients that experience respiratory failure after being liberated from mechanical ventilation.  
These findings are consistent with those found by Hernadez et al. (2016) and Stephan et al. (2015).  The 
number of subjects requiring re-intubation was also similar across studies, Hernadez et al, 2015 (HFNC 
22.8%, CPAP/BiPAP 19.1%) and Stephan et al., 2016 (HFNC 21%, CPAP/BiPAP 21.9%).  Analysis of 
Group 2 suggests that there is no significant difference between the time NIV therapy was started and the 
need for intubation.  As with Stephan et al. (2016), this study found that there was no significant 
reduction in mortality between HFNC therapy and CPAP/BiPAP when used to treat post extubation acute 
respiratory failure. 
Within both Group 1 and Group 2, the effects of various FiO2 and LPM settings were examined 
to determine associations with improved clinical outcomes (need for intubation or re-intubation, the 
hospital length of stay and mortality).  In comparing the interquartile ranges for FiO2 and LPM, this study 
suggests that there is no significant difference between HFNC therapy initial settings and clinical 
outcomes.  This finding suggests that variations in the amount of oxygen subjects received and the rate at 
which it was delivered have no impact on whether a patient died, required intubation or re-intubation and 
the hospital length of stay.  The inability of this study to detect a significant difference between FiO2 and 
LPM setting and the need for intubation or re-intubation could be due to the study being underpowered. 
In this study, current practices for HFNC therapy were assessed. It was found that there was a 
large variance in practices in the initial settings that are used.  In Group 1, FiO2 setting ranged from 40% 
to 100% with a median of 70%.  The flow rate was also found to have a large variance in the settings that 
were administered.  Patients in Group1 received oxygen at a flow rate ranging from 9 LPM to 40 LPM, 
with a median flow rate of 25 LPM.  In Group 2, there were a variety of HFNC settings for FiO2 and 
LPM used for initial therapy.  Flow rates in this group ranged from 10 to 40 LMP with a median flow rate 
of 25 LPM.  This study suggests that in current practice no equipoise of practice exists for initial settings 
of HFNC therapy. 
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Limitations and Strengths 
A limitation of this study was the design.  This study was designed to be a non-experimental, 
retrospective, medical chart review.  This is a known limitation because the data collected in the chart 
audit relied on the documentation of others.  Missing data in the charts led to the exclusion of 99 patients 
from the study.  This reduced the sample size, which may have reduced the ability of the study to discover 
any significant association between variables.  There were fewer patients in Group 2 than in Group 1.  
Group 2 had an unequal distribution of subjects between NIV therapies.  These factors could have skewed 
results and prevented significance from being detected. 
One strength of this study was the inclusion criteria for subjects.  Examination of a broad class of 
patient syndromes under the DRG parameters of acute respiratory failure may allow these results to be 
more generalizable.  Another strength of this study was that the inclusion and exclusion criteria were 
determined prior to data extraction from the electronic medical record.  In addition, the delineated 
structured randomized selection of patients was done to mitigate the risk of selection bias.  
Call for Future Research 
Further research into the effects of HFNC therapy is needed.  Large, robust, multicenter, 
prospectus, randomized controlled trials need to be conducted to establish the relationship between HFNC 
therapy vs. CPAP or BiPAP and intubation and in re-intubation rates.  As noted in the discussion, further 
studies need to illuminate the effects that delays in the initiation of post mechanical ventilator NIV have 
on intubation rates.  Continued research on this topic could increase knowledge of the best practices for 
de-escalation of therapy.  Further research needs to be conducted to better establish how various HFNC 
FiO2 and LPM settings impact patient care and clinical outcomes.  Increased research in this area can lead 
to a better understanding of HFNC therapy and help guide best practices for initiation and titration of 
therapy. 
Conclusion 
The aim of this study was to assess current practices of HFNC therapy to determine if it had an 
impact on intubation rates and clinical outcomes, as well as describe current practices to help guide 
clinicians in their use of HFNC therapy.  HFNC therapy has been shown to be non-inferior to CPAP or 
BiPAP in reducing the need for intubation/re-intubation, and clinical outcomes between groups were 
similar.  This combined with previous research demonstrating increased patient tolerance of HFNC 
therapy should lead to the continued adoption and use of this therapy.  This study was unable to establish 
which setting of FiO2 and LPM would be a best practice for this therapy.  As a result, clinicians should 
use their clinical expertise and patient response to guide which setting to use in the initiation of this 
therapy until future research can establish which settings are best practice.  
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Table 1 
 
Data points collected 
 
Data recorded Time data recorded 
Age At time of admission 
Sex At time of admission 
Primary diagnosis At time of admission 
Vital signs (HR, BP, Sp02, respiratory rate Every 4 hours starting at 0700, closest value 
Arterial Blood gases (ABGs) Closest value1 hour, 6 hours and 12 hours post oxygen 
supportive therapy initiation 
Noninvasive ventilation Type and Settings (HFNC or 
BIPAP/CPAP, and FiO2 and O2 L/min) 
Hourly setting and Type 
Ventilator settings (Mode, tidal volume, rate, FiO2, 
PEEP) 
First documented settings of the day 
Time on Noninvasive ventilation Documented start of noninvasive ventilation therapy to 
time of intubation 
Oxygen settings Every 4 hours starting at 0700, closest value 
PaO2/FiO2 ratio Closest value 1hour, 6 hours, 12 hours post noninvasive 
ventilation therapy 
Time of intubation Chest x-ray confirming endotracheal tube placement 
Time of extubation Documented time of extubation in chart 
Length of stay Time of admission to time of d/c or death 
Disposition 
DRG 
Time of discharge home or time of death 
At time of discharge 
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Table 2 
Characteristics of Group 1 
NIV therapy Age, mean + SD Sex, % (n) LOS, median DRG, median Mortality, %  (n) 
HFNC 
n=88 
57.80 + 16.66 M: 48.9% (43) 
F: 51.1% (45) 
14.82 days 3.16 Alive: 72.7% (64) 
Expired: 27.3% (24) 
 
CPAP or BiPAP  
n=125 
p value 
58.92 + 14.11 
 
p=0.188 
M: 58.4% (73) 
F: 41.6% (52) 
p=0.216 
10.65 days 
 
p=0.048 
1.88 
 
p=0.046 
Alive: 77.6% (97) 
Expired: 22.4% (28) 
p=0.415 
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Table 3 
Group 1: HFNC vs. CPAP or BiPAP and Intubation 
 HFNC therapy CPAP or BiPAP  p value 
Time on NIV, median 6.50 hours 4.0 hours p= <0.001 
Time on vent post NIV, median 94.0 hours 90.0 hours p= 0.801 
Need for intubation, % (no.) Yes: 24.4% (30) 
No: 75.6% (93) 
Yes: 35.2% (31) 
No: 64.8 % (57) 
p= 0.119 
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Table 4 
Group 1: HFNC FiO2 Setting and Clinical Outcomes 
Quartile (range) Mortality, % (no.) LOS, median Vent need, 
%(no.) 
Time on vent, 
median 
DRG, Median 
Q1 (40-55%) 
 
Q2 (56-70%) 
 
Q3 (71-99%) 
Alive: 76.2% (16) 
Expired: 23.8% (5) 
Alive: 80% (16) 
Expired: 20% (4) 
Alive: 85.7% (12) 
Expired: 14.3% (2) 
12.17 days 
 
12.50 days 
 
32.94 days 
 
Yes: 38.1% (8) 
No: 61.9% (13) 
Yes:  35% (7) 
No: 65% (13) 
Yes: 42.9% (6) 
No: 57.1% (8) 
51 hours 
 
94 hours 
 
267 hours 
   3.80 
 
   3.42 
 
   5.31 
Q4 (100%) 
 
p value 
Alive: 56.7% (17) 
Expired: 43.3% (13) 
p= 0.099 
11.70 days 
 
p= 0.062 
Yes: 36.7% (11) 
No: 63.3% (19) 
p= 0.992 
96 hours 
 
p= 0.082 
1.81 
 
p= 0.003 
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Table 5 
Group 1: HFNC LPM Setting and Clinical Outcomes 
Quartile (range) Mortality, % (no.) LOS, median Vent need, 
%(no.) 
Time on vent, 
median 
DRG, Median 
Q1 (9-20 LPM) 
 
Q2 (21-25 LPM) 
 
Q3 (26-30 LPM) 
Alive: 75% (9) 
Expired: 25% (3) 
Alive: 65.4% (17) 
Expired: 34.6% (9) 
Alive: 68.4% (13) 
Expired: 31.6% (6) 
2.77 days 
 
 12.78 days 
 
17.77 days 
 
Yes: 41.7% (5) 
No: 58.3% (7) 
Yes: 34.6% (9) 
No: 65.4% (17) 
Yes: 47.4% (9) 
No: 52.6% (10) 
51 hours 
 
42 hours 
 
191 hours 
  2.05 
 
   5.00 
 
   6.85 
Q4 (30-40 LPM) 
 
p value 
Alive: 78.6% (22) 
Expired: 21.4% (6) 
p= 0.502 
14.65 days 
 
p= 0.476 
Yes: 32.1% (9) 
No: 67.9% (19) 
p= 0.716 
87 hours 
 
p= 0.046 
5.08 
 
p= 0.692 
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Table 6 
Characteristics of Group 2 
NIV Therapy Age, mean + SD Sex, % (no.) LOS, median DRG, median Mortality, % (no.) 
HFNC 
n=62 
51.50 + 16.94 M: 62.9% (39) 
F: 37.1% (23) 
16.08 5.17 Alive: 85.5% (53) 
Expired: 14.5% (9) 
CPAP or 
BiPAP  
n=26 
p value 
58.62 + 15.25 
 
p= 0.041 
M: 50% (13) 
F: 50% (13) 
p= 0.376 
18.16 
 
p= 0.387 
5.37 
 
p= 0.905 
Alive: 88.5% (23) 
Expired: 11.5% (3) 
p= 0.975 
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Table 7 
Group 2: HFNC vs. CPAP or BiPAP and Re-intubation 
 HFNC therapy CPAP or BiPAP  p value 
Time on NIV, median 34 hours 8.50 hours   p= <0.001 
Need for re-intubation, %, (no.) Yes: 26.9% (7) 
No: 73.1% (19) 
Yes: 23.8% (15) 
No: 71.6% (48) 
p= 0.969 
Delay in NIV post vent, median  3 hours 1 hour p= 0.168 
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Table 8 
Group 2: HFNC FiO2 Setting and Clinical Outcomes 
Quartile (range) Mortality, % (no.) LOS, median Vent need, %(no.) DRG, Median 
Q1 (21-40%) 
 
Q2 (41-50%) 
 
Q3 (51-70%) 
Alive: 98.3% (15) 
Expired: 6.3% (1) 
Alive: 88.2% (15) 
Expired: 11.8% (2) 
Alive: 81.8 % (9) 
Expired: 18.2% (2) 
17.68 days 
 
15.89 days 
 
17.38 days 
 
Yes: 31.3% (5) 
No: 68.8% (11) 
Yes: 11.8% (2) 
No: 88.2% (15) 
Yes: 18.2 % (2) 
No: 81.8 % (9) 
5.54 
 
3.10 
 
5.34 
Q4 (71-100%) 
 
p value 
Alive: 77.8% (14) 
Expired: 22.2 (4) 
p= 0.167 
14.50 days 
 
p= 0.409  
Yes: 33.3% (6) 
No: 66.7% (12) 
p= 0.749 
   5.04 
 
p= 0.486 
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Table 9 
Group 2: HFNC LPM Setting and Clinical Outcomes 
Quartile (range) Mortality, % (no.) LOS, median Vent need, %(no.) DRG, Median 
Q1 (10-20 LPM) 
 
Q2 (21-25 LPM) 
 
Q3 (26-30 LPM) 
Alive: 87.2 % (7) 
Expired: 12.5 % (1) 
Alive: 82.4 % (14) 
Expired: 17.6% (3) 
Alive: 82.8% (24) 
Expired: 17.2% (5) 
25.28 days 
 
13.91 days 
 
18.63 days 
 
Yes: 37.5% (3) 
No: 62.5% (5) 
Yes: 11.8 % (2) 
No: 88.2% (15) 
Yes: 24.1% (7) 
No: 75.9 % (22) 
5.56 
 
5.03 
 
5.21 
Q4 (31-40 LPM) 
 
p value 
Alive: 100% (8) 
Expired: 0% (0) 
p= 0.554 
16.15 days 
 
p= 0.146  
Yes: 24.2% (3) 
No: 75.8% (5) 
p= 0.596 
 
2.99 
p= 0.423  
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Table 10 
FiO2 Settings and Time on NIV 
Quartiles Group 1 median time on NIV Group 2 median time on NIV 
Q1 12.00 hours 41.50 hours 
Q2 14.00 hours 41.00 hours 
Q3 25.00 hours 24.00 hours 
Q4 37.50 hours 34.50 hours 
p value p= 0.103 p= 0.624 
 
THE EFFECTS OF HFNC THERAPY AND INTUBATION  20
Table 11 
LPM Settings and Time on NIV 
Quartiles Group 1 median time on NIV Group 2 median time on NIV 
Q1 5.50 hours 10.0 hours 
Q2 30.50 hours 41.00 hours 
Q3 25.00 hours 40.00 hours 
Q4 30.50 hours 35.50 hours 
p value p= 0.033 p= 0.039 
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Figure 1. Sample Selection
Group	  2	  
92	  pa*ents	  receiving	  NIV	  post	  extuba*on	  
Group	  1	  
308	  pa*ents	  receiving	  NIV	  pre	  intuba*on	  
658	  soley	  receiving	  HFNC	  or	  CPAP	  Or	  BiPAP	  
200	  HFNC	  randomly	  selected	   200	  CPAP	  or	  BiPAP	  randomly	  selected.	  
1,885	  with	  primary	  or	  secondary	  diagnosis	  of	  Acute	  Respiratory	  Failure	  and	  on	  HFNC	  or	  CPAP/BiPAP	  
329	  soley	  receiving	  HFNC	   329	  soley	  receiving	  CPAP	  or	  BiPAP	   1,227	  receiving	  both	  therapies	  
Sample	  
	  46,218	  Adult	  admissions	  at	  UK	  Chandler	  Hospital	  July,	  1	  2011-­‐July1,	  2014	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